Kinase inhibitors in the treatment of renal cell carcinoma

被引：32

作者：

Larkin, James M. G. ^{[1
]}

Eisen, Tim ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2006年 / 60卷 / 03期

关键词：

renal cell carcinoma; metastatic; systemic therapy; kinase inhibition; targeted drugs;

D O I：

10.1016/j.critrevonc.2006.06.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy confers a small but significant overall survival advantage in metastatic renal cell carcinoma (RCC) but a need exists to develop more effective systemic therapies. Angiogenesis has a key role in the pathophysiology of renal cell carcinoma and vascular endothelial growth factor (VEGF) is an important mediator of this process. Sunitimb, sorafenib and axitinib are new agents which belong to a class of drugs called kinase inhibitors and inhibit the VEGF, platelet-derived growth factor (PDGF) and c-KIT receptor tyrosine kinases. Ternsirolimus inhibits the mammalian target of rapamycin (mTOR). All these agents have shown significant activity with manageable toxicity in metastatic RCC in phase 2 studies in patients generally pretreated with immunotherapy, whilst prolonged progression-free survival in a phase 3 study has been reported with sorafenib in comparison with placebo. Further phase 3 trials are recruiting and the combination of kinase inhibitors with other therapies is under investigation. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

引用

页码：216 / 226

页数：11

共 97 条

[1] Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer [J].

Atkins, M ;

Regan, M ;

McDermott, D ;

Mier, J ;

Stanbridge, E ;

Youmans, A ;

Febbo, P ;

Upton, M ;

Lechpammer, M ;

Signoretti, S .

CLINICAL CANCER RESEARCH, 2005, 11 (10) :3714-3721

[2] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[3] Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy:: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) [J].

Atzpodien, J ;

Schmitt, E ;

Gertenbach, U ;

Fornara, P ;

Heynemann, H ;

Maskow, A ;

Ecke, M ;

Wöltjen, HH ;

Jentsch, H ;

Wieland, W ;

Wandert, T ;

Reitz, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (05) :843-846

[4] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours [J].

Awada, A ;

Hendlisz, A ;

Gil, T ;

Bartholomeus, S ;

Mano, M ;

de Valeriola, D ;

Strumberg, D ;

Brendel, E ;

Haase, CG ;

Schwartz, B ;

Piccart, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (10) :1855-1861

[5] Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma [J].

Beck, SDW ;

Patel, MI ;

Snyder, ME ;

Kattan, MW ;

Motzer, RJ ;

Reuter, VE ;

Russo, P .

ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (01) :71-77

[6]

Brauch H, 2000, CANCER RES, V60, P1942

[7] Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy [J].

Bujassoum, S ;

Rifkind, J ;

Lipton, JH .

LEUKEMIA & LYMPHOMA, 2004, 45 (02) :401-403

[8] Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer [J].

Chang, J ;

Powles, TJ ;

Allred, DC ;

Ashey, SE ;

Clark, GM ;

Makris, A ;

Assersohn, L ;

Gregory, RK ;

Osborne, CK ;

Dowsett, M .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3058-3063

[9] Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma [J].

Cheville, JC ;

Lohse, CM ;

Zincke, H ;

Weaver, AL ;

Blute, ML .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (05) :612-624

[10] Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial [J].

Clark, JI ;

Atkins, MB ;

Urba, WJ ;

Creech, S ;

Figlin, RA ;

Dutcher, JP ;

Flaherty, L ;

Sosman, JA ;

Logan, TF ;

White, R ;

Weiss, GR ;

Redman, BG ;

Tretter, CPG ;

McDermott, D ;

Smith, JW ;

Gordon, MS ;

Margolin, KA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3133-3140

← 1 2 3 4 5 6 7 8 9 10 →